US 11,441,123 B2 · Method for evaluating quality of human mesenchymal stem cell, and monoclonal antibody for use in said method

Abstract

The present invention aims to obtain a method for quality evaluation of human mesenchymal stem cells, a method for isolation, selection and culture of human mesenchymal stem cells, a cell population of rapidly proliferating human mesenchymal stem cells, as well as monoclonal antibodies that specifically recognize rapidly proliferating human mesenchymal stem cells. From a cell population containing human mesenchymal stem cells, rapidly proliferating human mesenchymal stem cells are isolated, selected and cultured. The abundance ratio of cells expressing Ror2 or Fzd5 in the cell population thus isolated, selected and cultured is quantified to determine whether or not each cell population is acceptable.

Claims7

Dependent claims

A method for selecting and isolating proliferating human mesenchmal stem cells, which comprises:

a step 1 where from a cell population containing primary human tissue-derived mesenchymal stem cells, rapidly proliferating human mesenchymal stem cells which are Ror231 cells are single-cell cultured on a culture vessel surface to produce a cell population from said single-cell;
and
a step 2 where the abundance ratio of cells expressing Ror2 collected from the cell population obtained in the step 1 is quantified and
a step 3 selecting and isolating only the cell population to be at least 63% Ror2−.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

17/190,192Filed 2 Mar 2021 · continuation

Priority

JP 2014-1573671 Aug 2014

Published

US 2021/0230553 A129 Jul 2021

Granted

13 Sep 2022

Term ends

Not estimatedThe source records don’t support an estimate.

Classification16 codes

C12N 5/0663
Stem cells: bone marrow mesenchymal stem cells
C07K 16/28
Against material from animals or humans: against receptors, cell surface antigens or cell surface determinants
C12N 15/02
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or…:…
C12P 1/00
Preparation of compounds or compositions, not provided for in groups c12p3/00 -

Family

PCT/JP2015/071770Parent of this continuation · filed 31 Jul 2015

US 2021/0230553 A1Pre-grant publication · published 29 Jul 2021

Application15/321,679Parent of this continuation

US 2017/0204374 A1Published application

US 11,441,123 B2This patent

From the US filing history. Foreign family members aren’t listed.

Method for evaluating quality of human mesenchymal stem cell, and monoclonal antibody for use in said method

Life of this patent

Method for evaluating quality of human mesenchymal stem cell, and monoclonal antibody for use in said method

Life of this patent

Abstract

Claims7